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roxychloroquine (HCQ) therapy of chronic GVHD. The omission itself may be understandable, since other drugs such as rapamycin and deoxyspergualin were also omitted, and it is a challenge to be comprehensive in a rapidly changing field. However, it is important to mention hydroxychloroquine because of the current status of clinical trials. We have published extensively on the immunomodulatory effects of HCQ on alloreactivity, immune responses, and preclinical GVHD models. [3] [4] [5] [6] [7] [8] A phase II trial of HCQ has been presented twice.
9,10 The manuscript describing this trial is in press.
11
Most importantly, a very large phase III trial comparing standard therapy (prednisone/CsA) in combination with HCQ or placebo will open in July 2000. The trial will be funded by the NIH and conducted by the Children's Oncology Group. The trial also includes extensive laboratory evaluations to evaluate the pathogenesis of cGVHD. The trial represents the first randomized phase III multi-center trial of chronic GVHD, and will hopefully initiate a new mechanism for rapidly advancing our understanding of chronic GVHD and for determining the effectiveness of treatment.
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Response from Dr Gaziev
In our review, 1 we discussed the current situation of treatment for chronic GVHD. Consequently, we mainly presented the results of frequently used treatment approaches for this complication. Obviously we did not analyse all experimental drugs reported in the literature. Regarding hydroxychloroquine therapy for chronic GVHD we will consider it in our further studies.
Conventional drugs (prednisone, cyclosporine or azathioprine) have been used in randomised and non-randomised trials as conventional therapy for chronic GVHD. 2 There are no convincing data published regarding the treatment of chronic GVHD with rapamycin or 15-deoxyspergualin. Regarding azathioprine, there must be caution when confirming 'worsened outcome when added to prednisone therapy'. The authors refer to the study of Sullivan et al. 3 This study was performed mainly in adult patients, while the efficacy and the safety of the addition of azathioprine to other immunosuppressive drugs as a part of combined treatment for chronic GVHD in paediatric patients have not yet been studied. Our results of using this drug as a part of combined immunosuppressive therapy (in the paediatric non-malignant BMT setting) resulted in high complete responses with acceptable morbidity and mortality (manuscript submitted to Bone Marrow Transplant).
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